Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense
2011

Using RSV to Target Prostate Cancer Cells

Sample size: 8 publication 10 minutes Evidence: moderate

Author Information

Author(s): Echchgadda Ibtissam, Chang Te-Hung, Sabbah Ahmed, Bakri Imad, Ikeno Yuji, Hubbard Gene B, Chatterjee Bandana, Bose Santanu

Primary Institution: The University of Texas Health Science Center at San Antonio

Hypothesis

Can the respiratory syncytial virus (RSV) effectively target and kill androgen-sensitive prostate cancer cells?

Conclusion

RSV shows potential as a therapeutic tool for treating both androgen-sensitive and androgen-independent prostate cancer by inducing cell death.

Supporting Evidence

  • RSV effectively induced apoptosis in LNCaP prostate cancer cells.
  • RSV showed higher infectivity in cancer cells compared to non-tumorigenic cells.
  • Impaired interferon response in LNCaP cells led to increased viral replication and oncolysis.

Takeaway

Researchers found that a virus called RSV can help kill prostate cancer cells without harming normal cells, making it a promising treatment option.

Methodology

The study involved in vitro and in vivo experiments to assess the oncolytic effects of RSV on prostate cancer cells.

Potential Biases

Potential bias due to the use of specific cell lines and animal models that may not reflect human responses.

Limitations

The study primarily focused on specific cancer cell lines and may not fully represent all prostate cancer types.

Participant Demographics

The study used human prostate cancer cell lines and murine models.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-11-43

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication